Ignite Creation Date:
2024-10-26 @ 3:42 PM
Last Modification Date:
2024-10-26 @ 3:42 PM
Study NCT ID:
NCT06642909
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-10-13
Brief Title:
A Phase II Study of Zuberitamab Injection in Patients With Primary Membranous Nephropathy
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Multicenter Randomized Open Label Cyclosporine Controlled Phase II Clinical Study Evaluating the Efficacy and Safety of Zuberitamab Injection HS006 in Patients With Primary Membranous Nephropathy
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is a multicenter randomized open label cyclosporine controlled Phase II trial aimed at evaluating the efficacy safety pharmacokinetics and immunogenicity of Zuberitamab in patients with primary membranous nephropathy and exploring the Phase III dosing regimen sample size and endpoint evaluation time
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None